| Original language | English (US) |
|---|---|
| Journal | SKIN: Journal of Cutaneous Medicine |
| Volume | 6 |
| Issue number | 2 |
| DOIs |
|
| State | Published - Mar 4 2022 |
ASJC Scopus subject areas
- Dermatology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: SKIN: Journal of Cutaneous Medicine, Vol. 6, No. 2, 04.03.2022.
Research output: Contribution to journal › Comment/debate › peer-review
}
TY - JOUR
T1 - Tapinarof Cream 1% Once Daily for Plaque Psoriasis
T2 - Secondary Efficacy Outcomes from Two Pivotal Phase 3 Trials
AU - Gold, Linda Stein
AU - Blauvelt, Andrew
AU - Armstrong, April
AU - Desai, Seemal R.
AU - Sofen, Howard
AU - Green, Lawrence J.
AU - Tyring, Stephen K.
AU - Ferris, Laura K.
AU - Brown, Philip M.
AU - Rubenstein, David S.
AU - Piscitelli, Stephen C.
AU - Tallman, Anna M.
AU - Kircik, Leon
N1 - Funding Information: The authors thank the participating investigators, patients and their families, and colleagues involved in the conduct of the trials. L.S.G. has served as a consultant, and/or has received payment for the development of educational presentations, and/or has received grants from Arcutis, Amgen, Bristol-Myers Squibb, Dermavant Sciences, Inc., Eli Lilly, LEO Pharma, Ortho Dermatologic, and UCB Biopharma. A.B. has served as a scientific adviser and/ or clinical study investigator for AbbVie, Abcentra, Aligos, Almirall, Amgen, Arcutis, Arena, Aslan, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant Sciences, Inc., Eli Lilly and Company, Evommune, Forte, Galderma, Incyte, Janssen, Landos, Leo, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB Pharma. A.A. is a research investigator and/or scientific advisor to AbbVie, Bristol-Myers Squibb, Boehringer Ingelheim, EPI, Incyte, Leo, UCB, Janssen, Lilly, Novartis, Ortho Dermatologics, Sun, Dermavant Sciences Inc., Dermira, Sanofi, Regeneron, Pfizer, and Modmed. S.R.D. declares no financial relationships. H.S. has served as scientific adviser and/or clinical study investigator for AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Sciences Inc., Eli Lilly, Incyte, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi-Genzyme, Sun Pharma, and UCB. L.J.G. is an investigator, speaker, or consultant for Amgen, AbbVie, Arcutis, Bristol-Myers Squibb, Dermavant, Lilly, MC-2, Orthoderm, SunPharma, and UCB. S.K.T. participated in studies sponsored by Dermavant, the manufacturer of tapinarof. L.K.F. is an investigator for AbbVie, Amgen, Arcutis, Bristol-Myers Squibb, Boehringer Ingelheim, Dermavant, Eli Lilly, Galderma, Janssen, Novartis, Regeneron and UCB, and a consultant for AbbVie, Arcutis, Bristol-Myers Squibb, Dermavant, Eli Lilly, Janssen, Pfizer, and Sun Pharma. P.M.B., D.S.R., S.C.P., and A.M.T. are employees of Dermavant Sciences Inc., with stock options. Editorial and medical writing support under the guidance of the authors was provided by ApotheCom, UK, and was funded by Dermavant Sciences, Inc. in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med. 2015;163:461–464). Funding Information: The authors thank the participating investigators, patients and their families, and colleagues involved in the conduct of the trials. L.S.G. has served as a consultant, and/or has received payment for the development of educational presentations, and/or has received grants from Arcutis, Amgen, Bristol-Myers Squibb, Dermavant Sciences, Inc., Eli Lilly, LEO Pharma, Ortho Dermatologic, and UCB Biopharma. A.B. has served as a scientific adviser and/ or clinical study investigator for AbbVie, Abcentra, Aligos, Almirall, Amgen, Arcutis, Arena, Aslan, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant Sciences, Inc., Eli Lilly and Company, Evommune, Forte, Galderma, Incyte, Janssen, Landos, Leo, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB Pharma. A.A. is a research investigator and/or scientific advisor to AbbVie, Bristol-Myers Squibb, Boehringer Ingelheim, EPI, Incyte, Leo, UCB, Janssen, Lilly, Novartis, Ortho Dermatologics, Sun, Dermavant Sciences Inc., Dermira, Sanofi, Regeneron, Pfizer, and Modmed. S.R.D. declares no financial relationships. H.S. has served as scientific adviser and/or clinical study investigator for AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Sciences Inc., Eli Lilly, Incyte, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi-Genzyme, Sun Pharma, and UCB. L.J.G. is an investigator, speaker, or consultant for Amgen, AbbVie, Arcutis, Bristol-Myers Squibb, Dermavant, Lilly, MC-2, Orthoderm, SunPharma, and UCB. S.K.T. participated in studies sponsored by Dermavant, the manufacturer of tapinarof. L.K.F. is an investigator for AbbVie, Amgen, Arcutis, Bristol-Myers Squibb, Boehringer Ingelheim, Dermavant, Eli Lilly, Galderma, Janssen, Novartis, Regeneron and UCB, and a consultant for AbbVie, Arcutis, Bristol-Myers Squibb, Dermavant, Eli Lilly, Janssen, Pfizer, and Sun Pharma. P.M.B., D.S.R., S.C.P., and A.M.T. are employees of Dermavant Sciences Inc., with stock options. Editorial and medical writing support under the guidance of the authors was provided by ApotheCom, UK, and was funded by Dermavant Sciences, Inc. in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med. 2015;163:461–464). Contact Dr Linda Stein Gold at LSTEIN1@hfhs.org with questions or comments.
PY - 2022/3/4
Y1 - 2022/3/4
UR - http://www.scopus.com/inward/record.url?scp=85136406316&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85136406316&partnerID=8YFLogxK
U2 - 10.25251/skin.6.supp.6
DO - 10.25251/skin.6.supp.6
M3 - Comment/debate
AN - SCOPUS:85136406316
SN - 2574-1624
VL - 6
JO - SKIN: Journal of Cutaneous Medicine
JF - SKIN: Journal of Cutaneous Medicine
IS - 2
ER -